close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... 
Via Talk Markets
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
BeiGene's Brukinsa Approved In Europe For Rare Type Of Blood Cancer
The European Commission has approved BeiGene Ltd's (NASDAQ: BGNE) BRUKINSA (zanubrutinib) for Waldenström's macroglobulinemia (WM). WM is a type of... 
Via Benzinga
Week In Review: BeiGene Cleared To Stage $3 Billion IPO On Shanghai STAR Exchange
Beijing's BeiGene was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company's third listing. Previously, the company completed an $182 million IPO on the NASDAQ in 2016 and a $900... 
Via Talk Markets
Topics Initial Public Offering
Why BeiGene Shares Are Rising
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults... 
Via Benzinga
Week In Review: Two China Affiliated Biopharmas Raise $585 Million In IPOs
LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong... 
Via Talk Markets
Topics Initial Public Offering
Here's My Top Value Stock To Buy Right Now
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ... 
Via Benzinga
This Potential Indication Could Be a Winner for Novartis
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer. 
Via The Motley Fool
Notable Beigene Insider Trades $3.11 Million In Company Stock
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
Why BeiGene's Shares Jumped on Friday
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa. 
Via The Motley Fool
Beigene Insider Trades $33.79 Million In Company Stock
John Oyler, Chief Executive Officer at Beigene (NASDAQ:BGNE), made a large insider sell on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.... 
Via Benzinga
Topics Regulatory Compliance
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6... 
Via Benzinga
15 Stocks Moving in Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
Notable Beigene Insider Makes $4.62 Million Sale
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.... 
Via Benzinga
Topics Regulatory Compliance
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with ... 
Via Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Why Are Leap Therapeutics Shares Trading Higher On Monday?
Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company’s presentation of new data... 
Via Benzinga
Why BeiGene Stock Is Soaring This Week
The company won another FDA approval for blood cancer drug Brukinsa. 
Via The Motley Fool
BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication
The FDA has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM).... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today